| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:29294279 | IVTH | 0.000001 - 0.0001 M | 0.00001 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.0001 M | 0.00001 - 0.0001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:38266585 | IVR | 5.27 - 527 mg/kg/day | 5.27 - 527 mg/kg/day | Decreased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 52.7 - 527 mg/kg/day | 52.7 - 527 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 132 - 264 mg/kg/day | 132 - 264 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 26.4 - 264 mg/kg/day | 26.4 - 264 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 2.64 - 264 mg/kg/day | 2.64 - 264 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 2.64 - 264 mg/kg/day | 2.64 - 264 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 26.4 - 264 mg/kg/day | 26.4 - 264 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 26.4 - 264 mg/kg/day | 26.4 - 264 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 26.4 - 264 mg/kg/day | 26.4 - 264 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 26.4 - 264 mg/kg/day | 26.4 - 264 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 26.4 - 264 mg/kg/day | 26.4 - 264 mg/kg/day | Pregnancy complications | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.